Gilead Sciences Announces Fourth Quarter 2018 Dividend
Get Alerts GILD Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
EPS Growth %: -13.8%
Join SI Premium – FREE
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared a cash dividend of $0.57 per share of common stock for the fourth quarter of 2018. The dividend is payable on December 28, 2018, to stockholders of record at the close of business on December 14, 2018. Future dividends will be subject to Board approval.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181025005721/en/
Gilead Sciences, Inc.
Investors
Robin
Washington, 650-522-5688
or
Sung Lee, 650-524-7792
Source: Gilead Sciences, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Adecoagro Completes Acquisition of Caarapó Mill and Integrates It Into Its Cluster in Mato Grosso do Sul
- Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway
- Pennant Group to Participate in the 2026 Jefferies Healthcare Services Conference
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Twitter, DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share